GET DAILY SIGNALSAura Biosciences (AURA): Analyst Consensus Points to $19 Target and +190% Upside
Key Takeaways
- The central target of $19 is the arithmetic mean of three verified, current analyst price targets reviewed for Aura Biosciences, Inc. (AURA).
- The verified targets range from a low of $15 (Evercore ISI) to a high of $23 (LifeSci Capital), a wide spread that reflects genuine uncertainty around clinical-stage biotech.
- At the latest verified close of $6.56, reaching $19 implies roughly 190% upside, an unusually large move even by analyst-consensus standards.
- Support rests on bel-sar, the company's lead virus-like drug conjugate (VDC) candidate in late-stage development for primary choroidal melanoma and early-stage trials in bladder cancer.
- The biggest risks are binary clinical outcomes, a pre-revenue business model, and the fact that one firm (H.C. Wainwright) cut its target from $24 to $18.
- Aura Biosciences is a clinical-stage, development-focused company with no approved product yet, so valuation depends heavily on trial results and cash runway.
- Readers can explore the ticker's Major News, Today's Price Move, Forecast, and Earnings on dedicated pages for more detail.
- For additional context, explore Trending AI Robots to see AI-driven strategies monitoring this and other tickers.
Analyst Price Targets and Consensus View
The $19 central target is calculated from three current, attributable analyst price targets. LifeSci Capital maintains a Buy with a $23 target (August 2026), H.C. Wainwright reiterated Buy while lowering its target from $24 to $18 (August 2026), and Evercore ISI holds Buy at $15 after raising it from $13 (May 2026). Averaging these three yields $18.67, rounded to $19. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The $15–$23 range is unusually wide, underscoring how much depends on clinical data rather than near-term financials. All three firms rate the stock a Buy, but the H.C. Wainwright reduction shows even bullish analysts are tempering assumptions. Other firms, including Leerink Partners and TD Cowen, carry Buy ratings without published numeric targets, so they are not included in the average. No firm currently publishes a Hold or Sell rating with a target.
Current Market Position and Path Toward the Target
Aura Biosciences closed at $6.56 on November 6, 2026, giving the company a market capitalization near $680 million. Reaching $19 requires roughly 190% appreciation, a very large move for any single 12-month window. The stock trades within a 52-week range of $4.73 to $9.54, meaning the central target sits well above the stock's prior peak.
Because Aura Biosciences is pre-revenue, the path toward the target is not driven by EPS revisions but by clinical milestones. A successful late-stage readout for bel-sar in primary choroidal melanoma, or encouraging early bladder-cancer data, could compress what is currently a steep discount between the share price and analyst targets. The company's cash position of roughly $324 million provides runway but also highlights that value creation hinges on regulatory and clinical progress.
What Could Support a Move Toward the Target
- Lead candidate bel-sar: Positive efficacy or safety data in primary choroidal melanoma, a rare ocular cancer with limited approved options, could materially re-rate the stock.
- Pipeline optionality: Early-stage bladder-cancer development broadens the addressable market beyond ocular oncology.
- Strong cash position: Roughly $324 million in cash reduces near-term dilution risk relative to many small biotechs.
- Analyst alignment: All published targets are Buy-rated, and two of three targets sit at $18 or above.
What Could Prevent the Target From Being Reached
- Binary clinical risk: A failed or inconclusive late-stage trial would likely invalidate the higher targets quickly.
- Pre-revenue model: With a trailing net loss near $131 million, the company depends on continued funding and eventual regulatory success.
- Analyst skepticism: H.C. Wainwright's target cut from $24 to $18 signals reduced conviction in one formerly bullish scenario.
- Dilution risk: Future equity raises to extend the cash runway could pressure the share price.
Technical Levels and Market Structure
The stock's 52-week high of $9.54 (set in May 2026) represents the first major resistance level, followed by the psychological $10 mark. On the downside, the $6 area has served as recent support, with the 52-week low of $4.73 acting as a deeper floor. Aura Biosciences trades below its 200-day moving average near $6.74, indicating the longer-term trend remains pressured even after a modest rebound, and a sustained move above the 52-week high would be required to build momentum toward the $19 target.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a roughly 12-month research horizon, though the specific horizon varies by firm and is not always disclosed. Key items to watch include the next quarterly report expected in November 2026, updates on bel-sar's late-stage ocular program, early bladder-cancer data, cash-burn trends and any financing announcements, and analyst target revisions. None of these provides a definitive forecast, but they are the clearest catalysts for a re-rating.
Final Assessment
The $19 central target, an average of three current analyst targets ranging from $15 to $23, implies roughly 190% upside from the latest price of $6.56—a very large move that would require Aura Biosciences to trade far above its 52-week high. Support comes from bel-sar's late-stage ocular program, optionality in bladder cancer, a strong cash position, and unanimous Buy ratings, while the obstacles are binary clinical risk, a pre-revenue profile, and already-visible analyst caution. Investors should monitor upcoming clinical readouts and the November earnings report, recognizing that analyst targets are estimates, not guarantees.
Exploring AI Daily Buy/Sell Signals for Context
In my own research process, Tickeron's AI Daily Buy/Sell Signals have proven useful for tracking names like this one. The system applies artificial intelligence to scan thousands of stocks and ETFs, producing Buy, Sell, or Hold signals based on technical behavior and market shifts. It offers an efficient way to monitor volatile, news-driven situations without replacing fundamental analysis, and I find it adds a practical layer when following clinical-stage companies where timing around data releases matters.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
AURA's Stochastic Oscillator reaches overbought zone
The Stochastic Oscillator for AURA moved into overbought territory on November 06, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 50-day moving average for AURA moved below the 200-day moving average on October 30, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AURA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on AURA as a result. In 80 of 112 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 71%.
The Moving Average Convergence Divergence (MACD) for AURA just turned positive on November 03, 2026. Looking at past instances where AURA's MACD turned positive, the stock continued to rise in 43 of 52 cases over the following month. The odds of a continued upward trend are 83%.
AURA moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +10.28% 3-day Advance, the price is estimated to grow further. Considering data from situations where AURA advanced for three days, in 212 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
The Aroon Indicator entered an Uptrend today. In 110 of 150 cases where AURA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.158) is normal, around the industry mean (3.498). P/E Ratio (-3.792) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 41 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. AURA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AURA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement